CDDO-dhTFEA
Based on 1 Customer Validation
CDDO-dhTFEA (RTA dh404) is a synthetic oleanane triterpenoid compound which potently activates Nrf2 and inhibits the pro-inflammatory transcription factor NF-κB. CDDO-dhTFEA restores hypertension (MAP), increases Nrf2 and expression of its target genes, attenuates activation of NF-κB and transforming growth factor-β pathways, and reduces glomerulosclerosis, interstitial fibrosis and inflammation in the chronic kidney disease (CKD) rats.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.64%
- CAS No.: 1191265-33-4
- Formule: C33H45F3N2O3
- Masse moléculaire:574.72
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
IC50 & Target
[1]|
Nrf2 |
NF-κB |
In Vitro
CDDO-dhTFEA (0-500 nM, 24 h) upregulates the expression of antioxidant enzymes such as HO-1, SOD, catalase, and GCLC, reduces H2O2-induced oxidative stress, and inhibits apoptosis in human pancreatic tissue[3].
CDDO-dhTFEA (0-500 nM, 24 h) reduces the production of cytokines and chemokines (IL-1β, Il-4, and IFN-γ) in human pancreatic tissue[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human pancreatic tissue
-
Concentration:0-500 nM
-
Incubation Time:24 h
-
Result:Maintained the cell viability which is reduced by H2O2.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:L-arginine (HY-N0455) or Cholecystokinin (HY-P2932)-induced acute pancreatitis model[3]
-
Dosage:1 mg/kg
-
Administration:po, administered once 24 hours before induction of pancreatitis, then once daily for 3 days.
-
Result:Reduced inflammatory cell infiltration, destruction of acinar architecture, peripheral edema, and necrosis.
Reduced the serum amylase level of rats.
Reduced the MDA level of the pancreas of rats.
Chemical Information
-
CAS No. 1191265-33-4
-
Appearance Solid
-
Masse moléculaire 574.72
-
Formule C33H45F3N2O3
-
Color White to off-white
-
SMILES
CC(C)([C@](CC[C@@]([C@@]1(CC[C@]2(CCC(C)(C[C@]2([C@]13[H])[H])C)C(NCC(F)(F)F)=O)C)4C)5[H])C(C(C#N)=C[C@]5(C)[C@@]4([H])CC3=O)=O
-
Synonyms
RTA dh404
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (174.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.72 mg/mL (2.99 mM); Clear solution
This protocol yields a clear solution of ≥ 1.72 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (17.2 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Aminzadeh MA, et al. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease. Redox Biol. 2013 Oct 31;1:527-31. [Content Brief]
[2]. Aminzadeh MA, et al. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease. Xenobiotica. 2014 Jun;44(6):570-8. [Content Brief]
[3]. Robles L, et al., Synthetic Triterpenoid RTA dh404 (CDDO-dhTFEA) Ameliorates Acute Pancreatitis. Pancreas. 2016 May-Jun;45(5):720-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7400 mL | 8.6999 mL | 17.3998 mL | 43.4994 mL |
| 5 mM | 0.3480 mL | 1.7400 mL | 3.4800 mL | 8.6999 mL | |
| 10 mM | 0.1740 mL | 0.8700 mL | 1.7400 mL | 4.3499 mL | |
| 15 mM | 0.1160 mL | 0.5800 mL | 1.1600 mL | 2.9000 mL | |
| 20 mM | 0.0870 mL | 0.4350 mL | 0.8700 mL | 2.1750 mL | |
| 25 mM | 0.0696 mL | 0.3480 mL | 0.6960 mL | 1.7400 mL | |
| 30 mM | 0.0580 mL | 0.2900 mL | 0.5800 mL | 1.4500 mL | |
| 40 mM | 0.0435 mL | 0.2175 mL | 0.4350 mL | 1.0875 mL | |
| 50 mM | 0.0348 mL | 0.1740 mL | 0.3480 mL | 0.8700 mL | |
| 60 mM | 0.0290 mL | 0.1450 mL | 0.2900 mL | 0.7250 mL | |
| 80 mM | 0.0217 mL | 0.1087 mL | 0.2175 mL | 0.5437 mL | |
| 100 mM | 0.0174 mL | 0.0870 mL | 0.1740 mL | 0.4350 mL |
CDDO-dhTFEA Related Classifications
HY-112671 Related Classifications
Powered by Bioz